Short-term atorvastatin treatment does not modify neointimal morphology but reduces MMP-2 expression in normocholesterolemic rabbit stented arteries

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 3, 2006, Pages 428-436

  Collin, Bertrand ^a,f   Busseuil, David ^a   Korandji, Claudia ^a   Zeller, Marianne ^a,b   Cottin, Yves ^b   Duvillard, Laurence ^c   Rioufol, Gilles ^d   Pitois Merli, Isabelle ^e   Rochette, Luc ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b Cardiology Department   (France)

^c HÔPITAL DU BOCAGE   (France)

^d HOSPICES CIVILS DE LYON   (France)

^e PFIZER INC   (United States)

^f IFR No 100   (France)

Author keywords

Atorvastatin; MMP 2; Neointima; Restenosis; Statin

Indexed keywords

ATORVASTATIN; CHOLESTEROL; COLLAGEN; GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 2; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ILIAC ARTERY; INTIMA; MACROPHAGE; MALE; MORPHOLOGY; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; SMOOTH MUSCLE FIBER; STENT; VASCULAR SMOOTH MUSCLE; ANIMAL; CHEMISTRY; ENZYMOLOGY; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; PATHOLOGY;

ANIMALS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; ILIAC ARTERY; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 2; MUSCLE, SMOOTH, VASCULAR; PYRROLES; RABBITS; STENTS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUNICA INTIMA;

EID: 33745713619     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000211706.64993.cc     Document Type: Article

References (53)

1. Li Z, Li L, Zielke HR, et al. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol. 1996;148:121-128.
2. Bendeck MP, Zempo N, Clowes AW, et al. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994;75:539-545.
3. Zempo N, Koyama N, Kenagy RD, et al. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol. 1996;16:28-33.
4. Kanda S, Kuzuya M, Ramos MA, et al. Matrix metalloproteinase and alphavbeta3 integrin-dependent vascular smooth muscle cell invasion through a type I collagen lattice. Arterioscler Thromb Vasc Biol. 2000;20:998-1005.
5. Kuzuya M, Kanda S, Sasaki T, et al. Deficiency of gelatinase a suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia. Circulation. 2003;108:1375-1381.
6. Negre-Aminou P, van Vliet AK, van Erck M, et al. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta. 1997;1345:259-268.
7. Gellman J, Ezekowitz MD, Sarembock IJ, et al. Effect of lovastatin on intimal hyperplasia after balloon angioplasty: a study in an atherosclerotic hypercholesterolemic rabbit. J Am Coll Cardiol. 1991;17:251-259.
8. Indolfi C, Cioppa A, Stabile E, et al. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol. 2000;35:214-221.
9. Feldman LJ, Mazighi M, Scheuble A, et al. Differential expression of matrix metalloproteinases after stent implantation and balloon angioplasty in the hypercholesterolemic rabbit. Circulation. 2001;103:3117-3122.
10. Busseuil D, Zeller M, Cottin Y, et al. Intramural neovascularization and haemorrhages are major long-term effects of intravascular gamma-radiation after stenting. Int J Radiat Biol. 2003;79:787-792.
11. Fukuda Y, Ishizaki M, Okada Y, et al. Matrix metalloproteinases and tissue inhibitor of metalloproteinase-2 in fetal rabbit lung. Am J Physiol Lung Cell Mol Physiol. 2000;279:L555-L561.
12. Kopp CW, Holzenbein T, Steiner S, et al. Inhibition of restenosis by tissue factor pathway inhibitor: in vivo and in vitro evidence for suppressed monocyte chemoattraction and reduced gelatinolytic activity. Blood. 2004;103:1653-1661.
13. Busseuil D, Zeller M, Cottin Y, et al. Late neointimal tissue growth behind the stent after intravascular gamma-radiation. Int J Radiat Oncol Biol Phys. 2004;58:259-266.
14. Auerbach BJ, Krause BR, Bisgaier CL, et al. Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: atorvastatin versus lovastatin. Atherosclerosis. 1995;115:173-180.
15. Shah VM, Mintz GS, Apple S, et al. Background incidence of late malapposition after bare-metal stent implantation. Circulation. 2002;106:1753-1755.
16. Rogers C, Edelman ER, Simon DI. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci USA. 1998;95:10134-10139.
17. Bustos C, Hernandez-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol. 1998;32:2057-2064.
18. Herdeg C, Fitzke M, Oberhoff M, et al. Effects of atorvastatin on in-stent stenosis in normo- and hypercholesterolemic rabbits. Int J Cardiol. 2003;91:59-69.
19. Serruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J. 1999;20:58-69.
20. Mulder HJ, Bal ET, Jukema JW, et al. Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial). Am J Cardiol. 2000;86:742-746.
21. Bonetti PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid lowering-are they clinically relevant?. Eur Heart J. 2003;24:225-248.
22. Tekin A, Tekin G, Guzelsoy D, et al. Effects of atorvastatin (10 mg) on hemostatic and inflammatory parameters in hyperlipidemic patients with angiographically proven coronary artery disease. Am J Cardiol. 2004;94:206-209.
23. Strauss BH, Robinson R, Batchelor WB, et al. In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases. Circ Res. 1996;79:541-550.
24. Aikawa M, Rabkin E, Okada Y, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation. 1998;97:2433-2444.
25. Strauss BH, Chisholm RJ, Keeley FW, et al. Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis. Circ Res. 1994;75:650-658.
26. Jenkins GM, Crow MT, Bilato C, et al. Increased expression of membrane-type matrix metalloproteinase and preferential localization of matrix metalloproteinase-2 to the neointima of balloon-injured rat carotid arteries. Circulation. 1998;97:82-90.
27. Webb KE, Henney AM, Anglin S, et al. Expression of matrix metalloproteinases and their inhibitor TIMP-1 in the rat carotid artery after balloon injury. Arterioscler Thromb Vasc Biol. 1997;17:1837-1844.
28. Coats WD Jr, Whittaker P, Cheung DT, et al. Collagen content is significantly lower in restenotic versus nonrestenotic vessels after balloon angioplasty in the atherosclerotic rabbit model. Circulation. 1997;95:1293-1300.
29. Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation. 2001;103:993-999.
30. Seabra MC, Brown MS, Goldstein JL. Retinal degeneration in choroideremia: deficiency of rab geranylgeranyl transferase. Science. 1993;259:377-381.
31. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol. 2003;23:769-775.
32. Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol. 1998;18:1671-1678.
33. Saren P, Welgus HG, Kovanen PT. TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol. 1996;157:4159-4165.
34. Mach F, Schonbeck U, Bonnefoy JY, et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation. 1997;96:396-399.
35. Galis ZS, Muszynski M, Sukhova GK, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res. 1994;75:181-189.
36. Yanagi H, Sasaguri Y, Sugama K, et al. Production of tissue collagenase (matrix metalloproteinase 1) by human aortic smooth muscle cells in response to platelet-derived growth factor. Atherosclerosis. 1991;91:207-216.
37. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001;103:926-933.
38. Wilson WR, Evans J, Bell PR, et al. HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2005;30:259-262.
39. Siegel-Axel DI, Runge H, Seipel L, et al. Effects of cerivastatin on human arterial smooth muscle cell growth and extracellular matrix expression at varying glucose and low-density lipoprotein levels. J Cardiovasc Pharmacol. 2003;41:422-433.
40. Grothusen C, Bley S, Selle T, et al. Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis. Atherosclerosis. 2005;182:57-69.
41. Tziakas DN, Chalikias GK, Parissis JT, et al. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration. Int J Cardiol. 2004;94:269-277.
42. Komatsu R, Ueda M, Naruko T, et al. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation. 1998;98:224-233.
43. Bellosta S, Bernini F, Ferri N, et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis. 1998;137(Suppl):S101-S109.
44. Jaschke B, Michaelis C, Milz S, et al. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovasc Res. 2005;68:483-492.
45. Erl W. Statin-induced vascular smooth muscle cell apoptosis: a possible role in the prevention of restenosis? Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:135-144.
46. Wang L, Chen J, Sun Y, et al. Regulation of connexin expression after balloon injury: possible mechanisms for antiproliferative effect of statins. Am J Hypertens. 2005;18:1146-1153.
47. Laufs U, Marra D, Node K, et al. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem. 1999;274:21926-21931.
48. Wong WW, Dimitroulakos J, Minden MD, et al. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002;16:508-519.
49. Cafforio P, Dammacco F, Gernone A, et al. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005;26:883-891.
50. Farb A, Kolodgie FD, Hwang JY, et al. Extracellular matrix changes in stented human coronary arteries. Circulation. 2004;110:940-947.
51. Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol. 2002;22:1452-1458.
52. Schafer K, Kaiser K, Konstantinides S. Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury. Thromb Haemost. 2005;93:145-152.
53. Ikeda U, Shimpo M, Ohki R, et al. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension. 2000;36:325-329.